Herein, we designed a larger-scale retrospective study to investigate whether patients of lung adenocarcinoma with susceptible EGFR mutations receiving a lower starting doses of afatinib had a similar clinical effectiveness and fewer severe ADRs compared with those taking a higher starting dose of afatinib in Taiwan. The gene discussed is EGFR; the disease is lung adenocarcinoma.